Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 729-739 , October 2009

Standardized methods for the production of high specific-activity zirconium-89

Received 14 April 2009 ,Revised 12 May 2009 ,Accepted 27 May 2009.

References 

  1. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjugate Chem. 2009;
  2. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757–778
  3. van Dongen GAMS, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379–1389
  4. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2–5
  5. Mustafa MG, West HIJ, O'Brien H, Lanier RG, Benhamou M, Tamura T. Measurements and a direct-reaction plus Hauser-Feshbach analysis of 89Y(p,n)89Zr, 89Y(p,2n)88Zr, and 89Y(p,pn)88Y reactions up to 40 MeV. Phys Rev C. 1988;38:1624–1637
  6. Hinrichsen PF. Decay of 78.4 hour zirconium-89. Nucl Phys A. 1968;118:538–544
  7. Verel I, Visser GWM, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GAMS. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl Med. 2003;44:1271–1281
  8. Lewis JS, Singh RK, Welch MJ. Long lived and unconventional PET radionuclides. In:  Pomper MG,  Gelovani JG editor. Chapter 18 in molecular imaging in oncology. New York (N.Y.): Informa Healthcare; 2009;p. 283–292
  9. Hohn A, Zimmermann K, Schaub E, Hirzel W, Schubiger PA, Schibli R. Production and separation of “non-standard” PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Quarterly J Nucl Med Mol Imaging. 2008;52:145–150
  10. Inarida M, Shimamura A. Separation of carrier-free zirconium from yttrium target. Rikagaku Kenkyusho Hokoku. 1970;46:63–65
  11. Link JM, Krohn KA, Eary JF, Kishore R, Lewellen TK, Johnson MW, et al. 89Zr for antibody labelling and positron tomography. J Labeled Compd Radiopharm. 1986;23:1296–1297
  12. DeJesus OT, Nickles RJ. Production and purification of 89Zr, a potential PET antibody label. Appl Radiat Isotopes. 1990;41:789–790
  13. Lahiri S, Mukhopadhyay B, Das NA. Simultaneous production of 89Zr and 90,91m,92mNb in alpha-particle activated yttrium and their separation by HDEHP. Appl Radiat Isotopes. 1997;48:883–886
  14. Kandil SA, Scholten B, Saleh ZA, Youssef AM, Qaim SM, Coenen HH. A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of 88Zr and 89Zr in proton induced reactions on yttrium. J Radioanal Nucl Chem. 2007;274:45–52
  15. Herscheid JDM, Vos CM, Hoekstra A. Manganese-52m for direct application: a new 52Fe/52mMn generator based on a hydroxamate resin. Int J Appl Radiat Isotopes. 1983;34:883–886
  16. Fadeeva VI, Tikhomirova TI, Yuferova IB, Kudryavtsev GV. Preparation, properties and analytical applications of silica with chemically grafted hydroxamic acid groups. Anal Chim Acta. 1989;219:201
  17. Meijs WE, Herscheid JDM, Haisma HJ, Wijbrandts R, van Langevelde F, van Leuffen PJ, et al. Production of highly pure no-carrier added 89Zr for the labelling of antibodies with a positron emitter. Appl Radiat Isotopes. 1994;45:1143–1147
  18. Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl Radiat Isotopes. 1991;42:199–201
  19. Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: a brief review. J Nucl Med. 2009;49:1114–1131
  20. Yoo J, Tang L, Perkins Todd A, Rowland Douglas J, Laforest R, Lewis Jason S, et al. Preparation of high specific activity (86)Y using a small biomedical cyclotron. Nucl Med Biol. 2005;32:891–897
  21. Meijs WE, Herscheid JDM, Haisma HJ, Pinedo HM. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isotopes. 1992;43:1443–1447
  22. Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS, et al. Performance measurement of the microPET Focus 120 scanner. J Nucl Med. 2007;48:1527–1535
  23. Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM, Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med. 2006;47:1136–1143
  24. Mealey J. Turn-over of carrier-free zirconium-89 in man. Nature. 1957;179:673–674
  25. Mealey J. Application of positron-emitting zirconium-89 for potential use in brain tumor localization. Surg Forum. 1958;9:718–721
  26. Meijs WE, Haisma HJ, Van der Schors R, Wijbrandts R, Van den Oever K, Klok RP, et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol. 1996;23:439–448
  27. Meijs WE, Haisma HJ, Klok RP, van Gog FB, Kievit E, Pinedo HM, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med. 1997;38:112–118
  28. Verel I, Visser GWM, Boerman O, Van Eerd J, Finn R, Boellaard R, et al. Long-lived positron emitters Zirconium-89 and Iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharmaceut. 2003;18:655–661
  29. Verel I, Visser GWM, Boellaard R, Boerman O, Van Eerd J, Snow GB, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in Xenograft-bearing nude mice. J Nucl Med. 2003;44:1663–1670
  30. Verel I, Visser GWM, Vosjan MJWD, Finn R, Boellaard R, Van Dongen GAMS. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2004;31:1645–1652
  31. Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, et al. PET Radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharmaceut. 2004;19:155–163
  32. Perk LR, Visser GWM, Vosjan MJWD, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody Cetuximab. J Nucl Med. 2005;46:1898–1906
  33. Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJWD, Visser GWM, Zijlstra JM, et al. Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337–1345
  34. Börjesson PKE, Jauw YWS, Boellaard R, de Bree R, Comans EFI, Roos JC, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133–2140
  35. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313–1319
  36. Perk LR, Stigter-van Walsum M, Visser GWM, Kloet RW, Vosjan MJWD, Leemans CR, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35:1857–1867
  37. Perk LR, Visser GWM, Budde M, Vosjan MJWD, Jurek P, Kiefer GE, et al. Facile radiolabeling of monoclonal antibodies and other proteins with zirconium-89 or gallium-68 for PET imaging using p-isothiocyanatobenzyl-desferrioxamine. Nature Protocols. 2008;
  38. Aerts HJWL, Dubois L, Perk L, Vermaelen P, van Dongen GAMS, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123–131
  39. Shure K, Deutsch M. Radiations from zirconium89. Phys Rev. 1951;82:122
  40. Lightbody DB. Mitchell GE, and Sayres A. 89Y(p,n)89Zr reaction. Phys Lett. 1965;15:155–157
  41. Mustafa MG, West HI, O'Brien H, Lanier RG, Benhamou M, Tamura T. Measurements and a direct-reaction-plus-Hauser-Feshbach analysis of 89Y(p,n)89Zr, 89Y(p,2n)88Zr, and 89Y(p,pn)88Y reactions up to 40 MeV. Phys Rev C. 1988;38:1624–1637
  42. Bard AJ, Parsons R, Jordan J. Standard Potentials in Aqueous Solutions, IUPAC. New York, USA: Marcel Dekker; 1985;
  43. Kobayashi T, Sasaki T, Takagi I, Moriyama H. Zirconium solubility in ternary aqueous system of Zr(IV)-OH-carboxylates. J Nucl Science Tech (Tokyo, Japan). 2009;46:142–148
  44. Sasaki T, Kobayashi T, Takagi I, Moriyama H. Hydrolysis constant and coordination geometry of zirconium(IV). J Nucl Science Tech (Tokyo, Japan). 2008;45:735–739
  45. Kobayashi T, Sasaki T, Takagi I, Moriyama H. Solubility of zirconium(IV) hydrous oxides. J Nucl Science Tech (Tokyo, Japan). 2007;44:90–94
  46. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35–43
  47. Verel I, Visser Gerard WM, van Dongen Guus A. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005;46(Suppl 1):164S–171S

PII: S0969-8051(09)00151-6

doi: 10.1016/j.nucmedbio.2009.05.007

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 729-739 , October 2009

Article Tools

* Image Usage & Resolution